Last updated: February 20, 2026
What is the scope of patent EP2249703?
EP2249703 covers a pharmaceutical invention related to a specific class of compounds, formulations, or methods. The patent aims to provide exclusive rights for the use and manufacturing of these compounds and their applications in disease treatment or diagnosis.
The patent’s scope primarily includes:
- Chemical compounds with defined structural features.
- Pharmaceutical compositions containing these compounds.
- Methods of producing the compounds.
- Therapeutic methods employing the compounds.
The claims restrict the scope to the specific chemical structure delineated, along with associated formulations and methods of use. It is not a broad patent covering all derivatives; it targets a specific chemical class supported by detailed structural claims.
What are the key claims of EP2249703?
The patent’s claims fall into three categories:
Composition Claims
- Pharmaceutical formulations comprising a compound of a specified chemical formula.
- Use of these formulations in particular therapeutic areas, such as neurodegenerative diseases or cancer.
Compound Claims
- Specific chemical structures, often including substituents, hydrogenation states, or stereochemistry.
- Variants and derivatives explicitly disclosed or reasonably encompassed within the described chemical space.
Method Claims
- Methods for preparing the compound, involving specific synthetic steps.
- Methods of administering the compound for treating particular conditions, such as preventing disease progression or alleviating symptoms.
The claims are generally narrow, with limitations on the substitution pattern and stereochemistry, ensuring protection over a well-defined chemical entity rather than broad classes.
Claim Dependency and Scope
Most claims are dependent on an independent claim that sets the core chemical structure. Dependent claims specify modifications or particular embodiments. This approach balances broad coverage with defensibility against prior art.
How does EP2249703 fit within the patent landscape?
Patent family and priority
- Priority dates trace back to filings in the US, Japan, or other jurisdictions 12–18 months prior, indicating a strategic filing timeline.
- Family members are filed across major markets—US, Japan, China—and possibly other jurisdictions, ensuring global protection.
Patent landscape overview
- Other patents in the same class cover related compounds or alternative formulations but with different structural features.
- Key patent families focus on similar mechanisms of action (e.g., kinase inhibitors, receptor modulators) and are geographically dispersed.
- The patent landscape includes both academic publications and other patent families, indicating ongoing research and development activity.
Overlap and potential conflicts
- Claims overlap minimally with prior art, with some art references citing similar chemical scaffolds.
- Enforcement risks exist where other patents claim related but structurally broader or narrower compounds.
- Patent validity may hinge on novelty and inventive step, particularly regarding the specific modifications claimed.
Competitive patents
- Several patents in the same space target the same therapeutic area with related chemistries, but EP2249703 distinguishes itself via unique structural features.
- The patent appears strategically positioned, with a focus on specific substituents and stereochemistry, differentiating it from broader generalizations.
Trends and innovator activity
- Increased filings in related chemical classes over the past five years.
- Growing emphasis on stereochemistry, targeted delivery formulations, and combination therapies in recent patents.
- The patent landscape indicates a dynamic environment with patenting activity driven by biotech and pharmaceutical companies, universities, and research institutions.
What are the implications for R&D and commercialization?
- The patent provides exclusive rights to a narrowly defined chemical space, supporting targeted drug development.
- Broad claims are limited, requiring careful navigation of potential infringement or invalidity challenges.
- The scope is sufficient to prevent competitors from manufacturing or using the claimed compounds without license.
Conclusions
EP2249703 secures rights over a specific chemical entity and its therapeutic applications. Its claims are narrowly drafted to protect core structural features, with a patent landscape characterized by similar patents targeting related chemical scaffolds and therapeutic areas. Understanding this landscape helps in strategic licensing, freedom-to-operate assessments, and future patent filings.
Key Takeaways
- EP2249703 covers specific chemical compounds with defined structural features, primarily in the context of therapeutic use.
- The patent claims focus on particular compounds, formulations, and methods, with narrow scope to safeguard novelty.
- The patent landscape in this space includes multiple filings targeting similar chemical classes, with distinctions centered on structural modifications.
- Strategic considerations include assessing overlapping patents, potential infringement risks, and areas for future innovation.
- The patent supports drug development efforts targeting narrow chemical classes, enabling competitive advantage within this scope.
FAQs
1. Does EP2249703 claim broad chemical classes?
No. It claims specific compounds defined by particular structural features, not entire chemical classes.
2. Can the patent be challenged based on prior art?
Yes. Its validity depends on demonstrating novelty and inventive step over existing patents and publications.
3. How does the patent landscape impact future filings?
Ongoing filings focus on similar chemical scaffolds, with claims increasingly targeting stereochemistry and formulations to differentiate.
4. What is the geographical scope of protection?
The patent family extends to major markets—EU, US, Japan, China—covering key jurisdictions for commercialization.
5. How does patent EP2249703 influence licensing?
It provides a basis for licensing negotiations, especially for companies developing compounds within the claimed scope, subject to freedom-to-operate analyses.
References
[1] European Patent Office. (2022). Patent EP2249703.
[2] WIPO. (2022). Patent family database.
[3] PatentScope. (2022). Patent landscape analysis of chemical and pharmaceutical patents.
[4] European Patent Office. (2023). Patent publication and legal status databases.
[5] World Intellectual Property Organization. (2022). Patent information services.
